1. Burgoyne PS，Baker TG. Oocyte depletion in XO mice and their XX sibs from 12 to 200 days post partum. J Reprod Fertil，1981 Jan，61（1）; 207-212.

2. Ebrahimi M，FA Asbagh. Pathogenesis and Causes of Premature Ovarian Failure: An Update，Royan Institute International Journal of Fertility and Sterility，2011，Jul-Sep，5（2）54-65.

3. Ludwig M，Strowitzki T（2010）Prämature Ovarialinsuffizienz，Gynäkologe（2010）DOI 10.1007/s00129-010-2601-x; Seite 1-13.

4. Alzubaidi NH，Chapin HL，Vanderhoof VH，et al. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol，2002，99（5 pt 1）: 720-725.

5. Lebovic DI. Premature ovarian failure: Think‘autoimmune disorder'，Sexuality，Reproduction ＆Menopause，2004 Dec，2（4）; 230-233 .

6. Vujović S，Ivović M，Tancić-Gajić M，et al. Premature ovarian failure. Srp Arh Celok Lek，2012 Nov-Dec，140（11-12）; 806-811.

7. Knauff EA，Eijkemans MJ，Lambalk CB，et al.Dutch Premature Ovarian Failure Consortium. Anti-Mullerian hormone，inhibin B，and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab，2009 Mar，94（3）; 786-792. doi: 10.1210/jc.2008-1818. Epub 2008 Dec 9.

8. Li HW，Anderson RA，Yeung WS，et al. Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea. Fertil Steril，2011 Sep，96（3）; 774-779. doi: 10.1016/j.fertnstert.2011.06.016. Epub 2011 Jul 7.

9. Rees M，Purdie D. Premature menopause: Management of the menopause: the handbook. 4th ed. London: Royal Society of Medicine Press Ltd，2006; 142-149.

10. Coulam CB，Adamson SC，Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol，1986，67 （4）; 604-606.

11. Conway GS. Premature ovarian failure. Br Med Bull，2000，56（3）: 643-649.

12. Van Kasteren YM，Schoemaker J. Premature ovarian failure: a systematic review on therapeutic intervention to restore ovarian function and achieve pregnancy. Hum Reprod update，1999，5（5）: 483-492.

13. Luborsky JL，Meyer P，Sowers MF，et al.Premature menopause in a multi-ethinic population study of the menopause transition. Hum Reprod，2003，18（1）: 199-206.

14. Coulam CB，Adamson SC，Annegers JF. Incidence of premature ovarian failure.Obstet Gynecol，1986，67 （4）: 604-606.

15. Van Kasteren YM，Schoemaker J. Premature ovarian failure: a systematic review on therapeutic intervention to restore ovarian function and achieve pregnancy. Hum Reprod update，1999，5（5）: 483-492.

16. Luborsky JL，Meyer P，Sowers MF，et al.Premature menopause in a multi-ethinic population study of the menopause transition. Hum Reprod，2003，18（1）: 199-206.

17. Goldenberg RL，Grodin RL，Rodbard D，et al. Gonadotropin in women with amenorrhea. The use of plasma follicle-stimulating hormone to differentiate women with and without ovarian follicles. Am J Obstet Gynecol，1973，116（7）: 1003-1012.

18. Conway GS，Kaltsas G，Patel A，et al.Characterization of idiophatic premature ovarian failure.Fertil Steril，1996，65（2）: 337-341.

19. Van Kasteren YM，Schoemaker J. Premature ovarian failure: a systematic review on therapeutic intervention to restore ovarian function and achieve pregnancy. Hum Reprod update，1999，5（5）: 483-492.

20. Alzubaidi NH，Chapin HL，Vanderhoof VH，et al.. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol，2002，99（5 pt 1）: 720-725.

21. AkbariAsbagh F，Ebrahimi M.A case report of spontaneous pregnancy during hormonal replacement therapy for premature ovarian failure. Iranian Journal of Reproductive Medicine，2011，9（1）: 47-49.

22. Bidet M，Bachelot A，Bissauge E，et al. J Clin Endocrinol Metab，2011 Dec，96（12）; 3864-3872.

23. Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med，2009，360（6）: 606-614.

24. Panay N，Kalu E. Management of premature ovarian failure. Best Prac Res Clin Obstet Gynecol，2009，23 （1）: 129-140

25. Rebar RW，Cedars MI. Hypergonadotropic form of amenorrhea in young women. Endocrinol Metab Clin North Am，1992，21（1）: 173-191.

26. Gücer F，Urdl W，Pieber D，et al .Pregnancies in patients with premature ovarian failure. Clin Exp Obstet Gynecol，1997，24; 130-132.

27. Lutjen PJ，Findlay JK，Trounson AO，et al Effect on plasma gonadotropins of cyclic steroid replacement in women with premature ovarian failure. J Clin Endocrinol Metab，1986，62; 419-423.

28. De Vos M. Devroey P. Fauser BC. Primary ovarian insufficiency. Lancet. 376（9744）; 911-21，2010.

29. De Vos M. Devroey P. Fauser BC. Primary ovarian insufficiency. Lancet，2010，376（9744）; 911-921.

30. Persani L，Rossetti R，Cacciatore C. Genes involved in human premature ovarian failure. Journal of Molecular Endocrinology，2010，45，257-279.

31. Fassnacht W，Mempel A，Strowitzki T，et al. Premature ovarian failure（POF）syndrome: towards the molecular clinical analysis of its genetic complexity. Curr Med Chem，2006，13（12）; 1397-1410.

32. Persani L，Rossetti R，Cacciatore C. Genes involved in human premature ovarian failure. Journal of Molecular Endocrinology，2010，45，257-279.

33. Conway GS. Premature ovarian failure. Br Med Bull，2000，56（3）; 643-649.

34. Nelson LM，Anasti JN，Kimzey LM，et al.Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab，1994 Nov，79（5）; 1470-1475.

35. Kim TJ，Anasti JN，Flack MR，et al. Nelson LM Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol，1997 May，89（5 Pt 1）; 777-779.

36. Conway GS，Kaltsas G，Patel A，et al. Characterization of idiopathic premature ovarian failure. Fertil Steril，1996 Feb，65（2）; 337-341.

37. Vegetti W，Grazia Tibiletti M，Testa G，et al. Inheritance in idiopathic premature ovarian failure: analysis of 71 cases. Hum Reprod，1998 Jul，13（7）; 1796-1800.

38. van Kasteren YM，Hundscheid RD，Smits AP，et al. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease？Hum Reprod，1999 Oct，14（10）; 2455-2459.

39. Torgerson DJ，Avenell A，Russell IT，et al.Factors associated with onset of menopause in women aged 45-49. Maturitas，1994 Aug，19（2）; 83-92.

40. Cramer DW，Xu H，Harlow BL. Family history as a predictor of early menopause. Fertil Steril，1995 Oct，64（4）; 740-745.

41. Snieder H，MacGregor AJ，Spector TD. Genes control the cessation of a woman's reproductive life: a twin study of hysterectomy and age at menopause. J Clin Endocrinol Metab，1998，83: 1875-1880.

42. Treloar SA，Do KA，Martin NG. Genetic influences on the age at menopause. Lancet，1998 Oct 3，352 （9134）; 1084-1085.

43. Conway GS. Premature ovarian failure.Curropin Obstet Gynecol，1997，9（3）: 202-206.

44. Zinn AR. The X chromosome and the ovary.J Soc Gynecol Investig，2001，（Suppl Proceeding 1）: 34-36.

45. Baronchelli S，Villa N，Redaelli S，et al. Investigating the role of X chromosome breakpoints in premature ovarian failure. Mol Cytogenet. 2012 Jul，16; 5（1）; 32. doi: 10.1186/1755-8166-5-32.

46. Deletion mapping of the testis determining locus with DNA probes in 46，XX males and in 46，XY and 46，X，dic（Y）females. Nucleic Acids Res，1986，14; 6489-6505.

47. Familial premature ovarian failure due to an interstitial deletion of the long arm of the X chromosome.N Engl J Med，1987，317; 125-131.

48. Thrapel AT，Anderson KP，Simpson JL，et al. Deletion（X）（q26.1→q28）in a proband and her mother: molecular characterization andphenotypic-karyotypicdeductions.Am J Hum Genet，1993，52; 463-471.

49. Marozzi A，Porta C，Vegetti W，et al. Mutation analysis of the inhibin alpha gene in a cohort of Italian women affected by ovarian failure. Hum Reprod，2002，17; 1741-1745.

50. Davison RM，Fox M，Conway GS. Mapping of the POF1 locus and identification of putative genes for premature ovarian failure. Mol Hum Reprod，2000，6; 314-318.

51. Powell CM，Taggart RT，Drumheller TC，et al.Molecular and cytogenetic studies of an X; autosome translocation in a patient with premature ovarian failure and review of the literature.Am J Med Genet，1994，52; 19-26.

52. Sala C，Arrigo G，Torri G，et al. Eleven X chromosome breakpoints associated with premature ovarian failure（POF）map to a 15-Mb YAG contig spanning Xq21.Genomics，1997，40; 123-131.

53. Zinn AR，Page DC，Fisher EM. Turner Syndrome: the case of the missing sex chromosome. Trends Genet，1993，9; 90-93.

54. Cordts EB，Christofolini DM，Dos Santos AA，et al. Genetic aspects of premature ovarian failure: a literature review. Arch Gynecol Obstet，2011 Mar，283（3）; 635-643.

55. Burgoyne PS，Baker TG. Oocyte depletion in XO mice and their XX sibs from 12 to 200 days post partum. J Reprod Fertil，1981 Jan，61（1）; 207-212.

56. Zinn AR，Tonk VS，Chen Z，et al. Am J Hum Genet. 1998 Dec; 63（6）; 1757-1766.

57. Rebar RW，Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril，1990，53; 804-810.

58. Check JH，Chase JS，Spence M .，Pregnancy in premature ovarian failure after therapy with oral contraceptives despite resistance to previous human menopausal gonadotropin therapy. Am J Obstet Gynecol，1989，160; 114-115

59. Hovatta O. Ovarian function and in vitro fertilization（IVF）in Turner syndrome. Pediatr Endocrinol Rev，2012 May，9 Suppl 2; 713-717.

60. Holland CM. 47，XXX in an adolescent with premature ovarian failure and autoimmune disease. J Pediatr Adolesc Gynecol，2001，14（2）: 77-80

61. Goswami D，Conway GS.Premature ovarian failure. Hum Reprod Update，2005，11（4）: 391-410.

62. Goswami R，Goswami D，Kabra M，et al. Prevalence of the triple X syndrome in phenotypically normal women with premature ovarian failure and its association with autoimmune thyroid disorders，2003 Oct，80 （4）; 1052-1054.

63. Pouresmaeill F，Fallahian M，Azizi F，et al. Chromosomal abnormalities in women with premature ovarian failure. J Reprod Infertil，2007，8（2）: 142-148

64. Laml T，Preyer O，Umek W，et al Genetic disorders in premature ovarian failure. Hum Reorod Update，2002，8（5））: 483-491.

65. Conway GC，Hettiarachchi S，Murray A，et al. Fragile X premutations in familial premature ovarian failure. Lancet，995，346; 309-310.

66. Taylor AE. Should women with premature menopause be screened for FMR-1 mutations？Menopause，2001 Summer，8（2）; 81-83

67. Marozzi A，Vegetti W，Manfredini E，et al. Association between idiopathic premature ovarian failure and fragile X premutation. Hum Reprod，2000 Jan，15（1）; 197-202.

68. 0Mallolas J，Duran M，Sánchez A J，et al. Implications of the FMR1 gene in menopause: study of 147 Spanish women. Menopause，2001 Summer，8（2）; 106-110.

69. Allingham-Hawkins DJ，Babul-Hirji R，Chitayat D，et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data. Am J Med Genet，1999 Apr 2，83（4）; 322-325.

70. Schwartz CE，Dean J，Howard-Peebles PN，et al. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet，1994 Jul 15，51（4）; 400-402.

71. Taylor AE. Should women with premature menopause be screened for FMR-1 mutations？Menopause，2001 Summer，8（2）; 81-83.

72. Mallolas J，Duran M，Sánchez A，et al. Implications of the FMR1 gene in menopause: study of 147 Spanish women. Menopause，2001 Summer，8（2）; 106-110

73. Schwartz CE，Dean J，Howard-Peebles PN，et al. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet，1994 Jul 15，51（4）; 400-402.

74. Kolibianakis EM，Venetis CA，Diedrich K，et al.Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis.Hum Reprod Update，2009 Nov-Dec，15（6）; 613-622.

75. Würfel W. Spektrum der Ovarialfunktion im Klimakterium: Praktische Bedeutung für Endokrinologie und Reproduktionsmedizin. J Gynäkol Endokrinol，2010，20（4）: 6-11.

76. Conway GS，Payne NN，Webb J，et al. Fragile X premutation screening in women with premature ovarian failure，1998 May，13（5）; 1184-1187.

77 Battaglia C，Salvatori M，Maxia N，et al. Adjuvant L-arginine treatment for in-vitro fertilization in poor responder patients. Hum Reprod，1999，14（7）: 1690-1697.

78. Gleicher N，Barad DH. Dehydroepiandrosterone（DHEA）supplementati in diminished ovarian reserve （DOR）. Reprod Biol Endocrinol，2011，9: 67.

79. Hagerman RJ，Leavitt BR，Farzin F，et al. Fragile X-associated tremor/ataxia syndrome（FXTAS）in females with FMR1 premutation. Am J Hum Genet，2004，74（5）: 1051-1056.

80. Van Esch H. The fragile X permutation: new insights and clinical consequences. Eur J Med Genet，2006，49 （1）: 1-8.

81. Dixit H，Rao L，Padmalatha V，et al. Genes governing premature ovarian failure. Reprod Biomed Online，2010 Jun，20（6）; 724-740.

82. Yakin K，Urman B. DHEA as a miracle drug in the treatment of poor responders; hype or hope？Hum Reprod，2011.Hreinsson J G，Otala M，Fridstorm M，et al. Follicles are found in the ovaries of adolescent girl with Turner's syndrome. J Clin Endocrinol Metab.2002; 87（8）: 3618-3623.

83. Shamilova NN，Marchenko LA，Dolgushina NV，et al. The role of genetic and autoimmune factors in premature ovarian failure. J Assist Reprod Genet. 2013 Jun; 30（5）; 617-622.

84. Anderson RA，Themmen AP，Al-Qahtani A，et al. The effects of chemotherapy and long-term gonadotropin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod，2006，21（10）: 2583-2592.

85. Heitz D，Devys D，Imbert G，et al. Inheritance of the fragile X syndrome: size of the fragile X premutation is a major determinant of the transition to full mutations. J Med Genet，1992，29; 794-801.

86. Platteau P，Sermon K，Seneca S，et al. Preimplantation genetic diagnosis for fragile Xa syndrome: difficult but not impossible. Hum Reprod，2002，17（11）: 2807-2812.

87. Wallace WH，Thomson AB，Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod，2003，18; 117.

88. De Vos M. Devroey P. Fauser BC. Primary ovarian insufficiency. Lancet，2010 Sep 11，376（9744）; 911-921.

89. Chang CL，Wang HS，Soong YK，et al. Regulation of oocyte and cumulus cell interactions by intermedin/ adrenomedullin 2，2011 Dec 16，286（50）; 43193-43203.

90. Di Pasquale E，Beck-Peccoz P，Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15（BMP15）gene. Am J Hum Genet，2004，75（1）: 106-111.

91. Bione S，Sala C，Manzini C，et al.，A human homologue of the Drosophila melanogaster diaphanous gene is disrupted in a patient with premature ovarian failure: evidence for conserved function in oogenesis and implications for human sterility. Am J Hum Genet，1998，62，533-541.

92. lumenfeld Z. Gynecologic concerns for young women exposed to gonadotoxic chemotherapy. Curr Opinion Obstet Gynecol，2003，15（5）: 359-370.

93. Castello-Branco C，Nomdedeu B，Camus A，et al. Use of gonadotropinreleasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril，2007，87（3）: 702-705.

94. Blumenfeld Z，Avivi I，Eckman A，et al. Gonadotropin-releasing hormone agonist decreases chemotherapyinduced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril，2008，89（1）: 166-173.

95. Rees M，Purdie D. Premature menopause: Management of the menopause: the handbook. 4th ed. London: Royal Society of Medicine Press Ltd，2006; 142-149.

96. Crisponi L，Deiana M，Loi A，，et al. The putative forkhead transcription factor FOXL2 is mutated in Blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet，2001，27（2）: 159-166..

97. De Baere E，Fellous M，Veitia RA. The transcription factor FOXL2 in ovarian function and dysfunction. Folia Histochem Cytobiol，2009，47（5）; 43-49.

98. Weigel D，H. Jäckle.The fork head domain: a novel DNA binding motif of eukaryotic transcription factors？Cell，1990 Nov 2，63（3）; 455-456.

99. Verdin H，De Baere E. FOXL2 impairment in human disease. Horm Res Paediatr，2012，77（1）; 2-11.

100. Laml T，Preyer O，Umek W，et al. Genetic disorders in premature ovarianfailure. Hum Reorod Update，2002，8（5）: 483-491.

101. Vujovic S. Aetiology of premature ovarian failure. Menopause Int，2009 Jun，15（2）; 72-75.

102. Ito Y，Fisher CR，Conte FA，et al. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. ProcNatlAcadSci USA，1993，90（24）: 11673-11677.

103. Latronico AC，Anasti J，Arnhold IJ，et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl Med，1996，334（8）: 507-512.

104. Meduri G，Touraine P，Beau I，et al. Delayed puberty and primary amenorrhea associated with a novel mutation of the follicle-stimulating hormone receptor; clinical，histological，molecular studies. J Clin Endocrinol Metab，2003，88（8）: 3491-3498.

105. Bretherick KL，Hanna CW，Currie LM，et al. Estrogen receptor alphagene polymorphisms are associated with idiopathic premature ovarian failure. Fertil Steril，2008，89（2）318-324.

106. Pyun JA，Kang H，Lee SK，et al. Association between polymorphisms in the protein L-isoaspartate （D-aspartate）O-methyltrans-ferase gene and premature ovarian failure. Fertil Steril，2009，91（Suppl 4）: 1362-1365.

107. Lumaka A，Mubungu G，Nsibu C，et al.X-linked adrenal hypoplasia congenita: a novel DAX1 missense mutation and challenges for clinical diagnosis in Africa，2012 Feb，171（2）; 267-270.

108. Cohen DP，Layman LC. Relevance of molecular medicine to clinical obstetrics and gynecology. Obstet Gynecol Surv，1997 Jan，52（1）; 73-80

109. Aittomäki K，Herva R，Stenman UH，et al. Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab，1996 Oct，81（10）; 3722-3726.

110. Aittomäki K，Herva R，Stenman UH，et al. Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab，1996 Oct，81（10）; 3722-3726.

111. Beau I，Touraine P，Meduri G，et al.. A novel phenotype related to partial loss of function mutations of the follicle stimulating hormone receptor. J Clin Invest，1998 Oct 1，102（7）; 1352-1359.

112. Jiang M，Aittomäki K，Nilsson C，et al. The frequency of an inactivating point mutation（566C--＞T）of the human follicle-stimulating hormone receptor gene in four populations using allele-specific hybridization and time-resolved fluorometry. J Clin Endocrinol Metab，1998 Dec，83（12）; 4338-4343.

113. Touraine P，Beau I，Gougeon A，et al.New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptor function and phenotype. Mol Endocrinol，1999 Nov，13（11）; 1844-1854.

114. Doherty E，Pakarinen P，Tiitinen A，et al.A Novel mutation in the FSH receptor inhibiting signal transduction and causing primary ovarian failure. J Clin Endocrinol Metab，2002 Mar，87（3）; 1151-1155.

115. Latronico AC，Anasti J，Arnhold IJ，et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl J Med，1996 Feb 22，334（8）; 507-512.

116. Latronico AC，Arnhold IJ Inactivating mutations of the human luteinizing hormone receptor in both sexes. Semin Reprod Med，2012 Oct，30（5）; 382-386.

117. Shelling AN，Burton KA，Chand AL，et al. Inhibin: a candidate gene for premature ovarian failure. Hum Reprod，2000 Dec，15（12）; 2644-2649.

118. Dixit H，Rao KL，Padmalatha V，et al.. Expansion of the germline analysis for the INHA gene in Indian women with ovarian failure. Hum Reprod，2006，21 ; 1643-1644

119. Marozzi A，Porta C，Vegetti W，et al. Mutation analysis of the inhibin alpha gene in a cohort of Italian women affected by ovarian failure. Hum Reprod，2002，17 ; 1741-1745

120. Chang SH，Kim CS，Lee KS，et al. Premopausal factors influencing premature ovarian failure and early menopause. Maturitas，2007，58（1）: 19-30.

121. Corre T，Schuettler J，Bione S，et al .Italian Network for the study of Ovarian Dysfunctions. Hum Reprod，2009 Aug，24（8）; 2023-2028.

122. Wheatcroft NJ，Salt C，Milford-Ward A，et al.Identification of ovarian antibodies by immunofluorescence，enzyme-linked immunosorbent assay or immunoblotting in premature ovarian failure. Hum Reprod，1997 Dec，12（12）; 2617-2622

123. Nelson LM. Autoimmune ovarian failure: Comparing the mouse model and the human disease. J Soc Gynecol Investig，2001，8（Suppl Proceedings 1）; 55-57.

124. Yan G，Schoenfeld D，Penney C，et al. Identification of premature ovarian failure patients with underlying autoimmunity. J Womens Health Gend Based Med，2000，9（3）: 275-287.

125. Panay N，Kalu E. Management of premature ovarian failure. Best Pract Res Clin Obstet Gynaecol，2009 Feb，23（1）; 129-140.

126. Kauffman RP，Castracane VD. Premature ovarian failure associated with autoimmune polyglandular syndrome: pathophysiological mechanisms and future fertility. J Womens Health（Larchmt），2003 Jun，12 （5）; 513-520.

127. Hoek A，Schoemaker J，Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev，1997，8; 107-134.

128. Sedmak，DD，Hart WR，Tubbs RR. Autoimmune oophoritis: a histopathologic study of involved ovaries with immunologic characterization of the mononuclear cell infiltrate. Int J Gynecol Pathol，1987，6; 73-81.

129. Bakalov VK，Anasti JN，CalisKA，et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46，XX spontaneous premature ovarian failure. Fertil Steril，2005，84（4）: 958-965.

130. Hoek A，Schoemaker J，Drexhage HA. Premature ovarian failure and ovarian autoimmunity. EndocrRev，1997，18（1）: 107-134.

131. Goswami D，Conway GS. Premature ovarian failure. Hum Reprod Update，2005，11（4）: 391-410.

132. Falorni A，Laureti S，Candeloro P，et al. Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil Steril，2002，78（2）: 270-279.

133. Bakalov VK，Vanderhoof VH，Bondy CA，et al. Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure. Hum Reprod. 2002; 17 （8）: 2096-2100.

134. Lebovic DI，Naz R. Prematureovarianfailure: Think autoimmune disorder. Sexual Reprod Menop，2004，2 （4）: 230-233.

135. Kim TJ，Anasti JN，Flack MR，et al. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol，1997 May，89（5 Pt 1）; 777-779.

136. Forges T，Monnier-Barbarino P，Faure GC，et al. Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update，2004 Mar-Apr，10（2）; 163-175.

137. Keshaavarz H，Hills SD，Kieke BA，et al. Hysterectomy surveillance-United States，1994-1999. Surveillance summaries，2002，51（ss05）: 1-8.

138. Rebar RW. Premature ovarian“failure”in the adolescent. Ann NY Acad Sci，2008，1135: 138-145.

139. Epstein RJ. Drug-induced DNA damage and tumorchemosensitivity.J Clin Oncol，1990，8; 2062.

140. Morgan S，Anderson RA，Gourley C，et al. How do chemotherapeutic agents damage the ovary？Hum Reprod Updat，2012 Sep-Oct，18（5）; 525-535.

141. Di Prospero F，Luzi S，Iacopini Z. Cigarette smoking damages women's reproductive life. Reprod Biomed Online，2004 Feb，8（2）; 246-247.

142. Torgerson DJ，Thomas RE，Reid DM. Mothers and daughters menopausal ages: is there a link？Eur J Obstet Gynecol Reprod Biol，1997 Jul，74（1）; 63-66.

143. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause，2012 Mar，19（3）; 257-271.

144. Luoma P，Melberg A，Rinne JO，et al. Parkinsonism，premature menopause，and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet，2004，364; 875-882.

145. van der Stege JG，Groen H，van Zadelhoff SJ，et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause，2008 Jan-Feb，15（1）; 23-31.

146. Vujovic S，Brincat M，Erel T，et al. European Menopause and Andropause Society.EMAS position statement: Managing women with premature ovarian failure. Maturitas，2010 Sep，67（1）; 91-93.

147. Meskhi A，Seif MW. Premature ovarian failure. Curr Opin Obstet Gynecol，2006 Aug，18（4）; 418-426.